Implementation of the World's largest measles-rubella mass vaccination campaign in Bangladesh: a process evaluation.
Bangladesh
Mass vaccination campaign
Measles and rubella
Process evaluation
‘Gavi’ and ‘immunization’
Journal
BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562
Informations de publication
Date de publication:
10 Jul 2019
10 Jul 2019
Historique:
received:
28
11
2018
accepted:
17
06
2019
entrez:
12
7
2019
pubmed:
12
7
2019
medline:
12
10
2019
Statut:
epublish
Résumé
Gavi, the Vaccine Alliance, supported a mass vaccination Measles-Rubella Campaign (MRC) in Bangladesh during January-February 2014. We conducted a mixed-method process evaluation to understand the successes and challenges in implementation of the MRC. We reviewed documents for the MRC and the immunization programme in Bangladesh; observed meetings, vaccination sessions, and health facilities; and conducted 58 key informant interviews, 574 exit interviews with caregivers and 156 brief surveys with stakeholders involved in immunization. Our theory of Change for vaccination delivery guided our assessment of ideal implementation milestones and indicators to compare with the actual implementation processes. We identified challenges relating to country-wide political unrest, administrative and budgetary delays, shortage of transportation, problems in registration of target populations, and fears about safety of the vaccine. Despite these issues, a number of elements contributed to the successful launch of the MRC. These included: the comprehensive design of the campaign; strong partnerships between immunization authorities in the government system, Alliance partners, and civil society actors; and motivated and skilled health workers at different levels of the health system. The successful implementation of the MRC in spite of numerous contextual and operational challenges demonstrated the adaptive capacity of the national immunization programme and its partners that has positive implications for future introductions of Gavi-supported vaccines.
Sections du résumé
BACKGROUND
BACKGROUND
Gavi, the Vaccine Alliance, supported a mass vaccination Measles-Rubella Campaign (MRC) in Bangladesh during January-February 2014.
METHODS
METHODS
We conducted a mixed-method process evaluation to understand the successes and challenges in implementation of the MRC. We reviewed documents for the MRC and the immunization programme in Bangladesh; observed meetings, vaccination sessions, and health facilities; and conducted 58 key informant interviews, 574 exit interviews with caregivers and 156 brief surveys with stakeholders involved in immunization. Our theory of Change for vaccination delivery guided our assessment of ideal implementation milestones and indicators to compare with the actual implementation processes.
RESULTS
RESULTS
We identified challenges relating to country-wide political unrest, administrative and budgetary delays, shortage of transportation, problems in registration of target populations, and fears about safety of the vaccine. Despite these issues, a number of elements contributed to the successful launch of the MRC. These included: the comprehensive design of the campaign; strong partnerships between immunization authorities in the government system, Alliance partners, and civil society actors; and motivated and skilled health workers at different levels of the health system.
CONCLUSIONS
CONCLUSIONS
The successful implementation of the MRC in spite of numerous contextual and operational challenges demonstrated the adaptive capacity of the national immunization programme and its partners that has positive implications for future introductions of Gavi-supported vaccines.
Identifiants
pubmed: 31291922
doi: 10.1186/s12889-019-7176-4
pii: 10.1186/s12889-019-7176-4
pmc: PMC6617646
doi:
Substances chimiques
Measles Vaccine
0
Rubella Vaccine
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
925Subventions
Organisme : GAVI Alliance
ID : BGT/287/214
Références
J Infect Dis. 2003 May 15;187 Suppl 1:S223-9
pubmed: 12721917
J Infect Dis. 2003 May 15;187 Suppl 1:S299-306
pubmed: 12721929
Emerg Infect Dis. 2004 Nov;10(11):2017-21
pubmed: 15550217
J Infect Dis. 2011 Jul;204 Suppl 1:S198-204
pubmed: 21666162
J Infect Dis. 2011 Jul;204 Suppl 1:S252-9
pubmed: 21666170
J Infect Dis. 2011 Jul;204 Suppl 1:S499-505
pubmed: 21666206
J Infect Dis. 2011 Jul;204 Suppl 1:S78-81
pubmed: 21666217
J Infect Dis. 2011 Jul;204 Suppl 1:S82-9
pubmed: 21666218
J Infect Dis. 2011 Jul;204 Suppl 1:S90-7
pubmed: 21666219
Vaccine. 2014 Nov 12;32(48):6505-12
pubmed: 25261379
Glob Health Sci Pract. 2014 Jan 15;2(1):117-29
pubmed: 25276567
BMC Public Health. 2015 Nov 05;15:1100
pubmed: 26541976
BMC Infect Dis. 2016 Aug 12;16:411
pubmed: 27519586
Global Health. 2016 Oct 12;12(1):63
pubmed: 27729081